Peter Lio, MD, of Medical Dermatology Associates of Chicago in Chicago, Illinois, discusses recent innovations in atopic dermatitis therapies with regard to JAK inhibitors. Dr. Lio discusses several new drugs in this class, including topical ruxolitinib, oral abrocitinib, and oral upadacitinib, and provides important guidance for practitioners treating their patients with these new therapies.

Dr. Chovatiya discusses a recent poster presented at the 2025 Revolutionizing Atopic Dermatitis Conference which evaluated the effectiveness of upadacitinib in achieving long-term maintenance of...
PLAY